Rush-Presbyterian-St. Luke's Medical Center in Chicago will receive the first commercial shipment of Acuson's AcuNav diagnostic ultrasound catheter, which was cleared for market by the FDA at the end of last year. The intracardiac ultrasound
Rush-Presbyterian-St. Luke's Medical Center in Chicago will receive the first commercial shipment of Acuson's AcuNav diagnostic ultrasound catheter, which was cleared for market by the FDA at the end of last year.
The intracardiac ultrasound technique works by inserting a catheter through the patient's femoral or jugular vein. Clinicians can then maneuver it into the right atrium or right ventricle of the heart. The catheter uses color Doppler to image blood flow.
Dr. Richard Trohman of Rush-Presbyterian-St. Luke's said the catheter will allow electrophysiologists to perform procedures they were previously unable to do, because the AcuNav images the heart from within. An Acuson Sequoia ultrasound system is also part of the purchase.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
2 Commerce Drive
Cranbury, NJ 08512